CA2479246C - Method for overexpression of zwitterionic polysaccharides - Google Patents

Method for overexpression of zwitterionic polysaccharides Download PDF

Info

Publication number
CA2479246C
CA2479246C CA2479246A CA2479246A CA2479246C CA 2479246 C CA2479246 C CA 2479246C CA 2479246 A CA2479246 A CA 2479246A CA 2479246 A CA2479246 A CA 2479246A CA 2479246 C CA2479246 C CA 2479246C
Authority
CA
Canada
Prior art keywords
polypeptide
seq
set forth
res02
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2479246A
Other languages
English (en)
French (fr)
Other versions
CA2479246A1 (en
Inventor
Laurie E. Comstock
Katja G. Weinacht
Michael J. Coyne
Denis L. Kasper
Arthur O. Tzianabos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of CA2479246A1 publication Critical patent/CA2479246A1/en
Application granted granted Critical
Publication of CA2479246C publication Critical patent/CA2479246C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
CA2479246A 2002-03-13 2003-03-13 Method for overexpression of zwitterionic polysaccharides Expired - Fee Related CA2479246C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36416802P 2002-03-13 2002-03-13
US60/364,168 2002-03-13
PCT/US2003/007775 WO2003077863A2 (en) 2002-03-13 2003-03-13 Method for overexpression of zwitterionic polysaccharides

Publications (2)

Publication Number Publication Date
CA2479246A1 CA2479246A1 (en) 2003-09-25
CA2479246C true CA2479246C (en) 2017-05-09

Family

ID=28041884

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2479246A Expired - Fee Related CA2479246C (en) 2002-03-13 2003-03-13 Method for overexpression of zwitterionic polysaccharides

Country Status (7)

Country Link
US (4) US7166455B2 (enExample)
EP (1) EP1483384B1 (enExample)
JP (1) JP4733349B2 (enExample)
AT (1) ATE541036T1 (enExample)
AU (2) AU2003218144B2 (enExample)
CA (1) CA2479246C (enExample)
WO (1) WO2003077863A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
CA2479246C (en) * 2002-03-13 2017-05-09 Laurie E. Comstock Method for overexpression of zwitterionic polysaccharides
CA2520865A1 (en) * 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
CN102276732B (zh) 2003-11-28 2016-01-20 伊士曼化工公司 纤维素共聚体和氧化方法
US8206726B2 (en) * 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
US20110002965A1 (en) * 2007-11-09 2011-01-06 Round June L Immunomodulating compounds and related compositions and methods
JP2011503104A (ja) * 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2011127302A2 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
WO2011146910A1 (en) 2010-05-20 2011-11-24 Round June L Antigen specific tregs and related compositions, methods and systems
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
EP2764090B1 (en) * 2011-10-03 2017-12-13 California Institute of Technology Generation of psa-only producing mutant strain
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3337321A4 (en) * 2015-08-19 2019-07-17 President and Fellows of Harvard College LIPIDED PSA COMPOSITIONS AND METHOD
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS618945A (ja) 1984-06-25 1986-01-16 Nec Corp 半導体集積回路装置
ATE107697T1 (de) * 1986-03-26 1994-07-15 Genexpress Aps Biologische eindämmung.
US4952524A (en) 1989-05-05 1990-08-28 At&T Bell Laboratories Semiconductor device manufacture including trench formation
KR940006696B1 (ko) 1991-01-16 1994-07-25 금성일렉트론 주식회사 반도체 소자의 격리막 형성방법
US5350941A (en) 1992-09-23 1994-09-27 Texas Instruments Incorporated Trench isolation structure having a trench formed in a LOCOS structure and a channel stop region on the sidewalls of the trench
US5433794A (en) 1992-12-10 1995-07-18 Micron Technology, Inc. Spacers used to form isolation trenches with improved corners
JPH07326664A (ja) 1994-05-31 1995-12-12 Fuji Electric Co Ltd ウエハの誘電体分離溝の充填方法
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5851808A (en) * 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
CA2479246C (en) * 2002-03-13 2017-05-09 Laurie E. Comstock Method for overexpression of zwitterionic polysaccharides
CA2520865A1 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy

Also Published As

Publication number Publication date
US20080057565A1 (en) 2008-03-06
US20070154991A1 (en) 2007-07-05
US7803602B2 (en) 2010-09-28
AU2003218144A1 (en) 2003-09-29
WO2003077863A2 (en) 2003-09-25
JP4733349B2 (ja) 2011-07-27
WO2003077863A3 (en) 2004-07-22
EP1483384A4 (en) 2006-11-02
EP1483384B1 (en) 2012-01-11
CA2479246A1 (en) 2003-09-25
US20030219413A1 (en) 2003-11-27
JP2005519617A (ja) 2005-07-07
AU2003218144B2 (en) 2008-08-14
US20070020730A1 (en) 2007-01-25
AU2008243143A1 (en) 2008-11-27
US7166455B2 (en) 2007-01-23
US7678558B2 (en) 2010-03-16
AU2008243143B2 (en) 2012-10-04
EP1483384A2 (en) 2004-12-08
ATE541036T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
US7678558B2 (en) Method for overexpression of zwitterionic polysaccharides
AU3976701A (en) Fibroblast growth factor-23 molecules and uses thereof
US20070010662A1 (en) VGF fusion polypeptides
AU783199B2 (en) VGF polypeptides and methods of treating VGF-related disorders
US8420332B2 (en) Tumor endothelial marker 5-α molecules and uses thereof
AU779614B2 (en) VGF selective binding agents and methods of treating VGF-related disorders
US20090053763A1 (en) Tumor endothelial marker 7-alpha molecules and uses thereof
US20070059723A1 (en) Secreted epithelial colon stromal-1 molecules and uses thereof
AU2003300395A1 (en) Wnt-1 inhibitory factor-1 (wif-1) molecules and uses thereof
US20060281149A1 (en) Transforming growth factor-beta-related molecules and uses thereof
AU2004308908B2 (en) HEH4 molecules and uses thereof
AU2007240151A1 (en) Tumor Endothelial Marker 7Alpha Molecules and Uses Thereof
AU2002303880A1 (en) Tumor endothelial marker 7a molecules and uses thereof
WO2003046127A2 (en) Tumor endothelial marker 5 molecules and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210315